BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation
NASDAQ:BTMD • US0906831039
Current stock price
1.47 USD
-0.13 (-8.13%)
At close:
1.42 USD
-0.05 (-3.4%)
After Hours:
This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BTMD Profitability Analysis
1.1 Basic Checks
- BTMD had positive earnings in the past year.
- BTMD had a positive operating cash flow in the past year.
- Of the past 5 years BTMD 4 years were profitable.
- Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 25.13%, BTMD belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 44.85%, BTMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for BTMD is significantly above the industry average of 13.06%.
- The 3 year average ROIC (32.37%) for BTMD is below the current ROIC(44.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.13% | ||
| ROE | N/A | ||
| ROIC | 44.85% |
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 14.07%, BTMD belongs to the top of the industry, outperforming 87.56% of the companies in the same industry.
- In the last couple of years the Profit Margin of BTMD has declined.
- BTMD's Operating Margin of 18.50% is amongst the best of the industry. BTMD outperforms 86.53% of its industry peers.
- BTMD's Operating Margin has declined in the last couple of years.
- The Gross Margin of BTMD (71.46%) is better than 79.27% of its industry peers.
- In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.5% | ||
| PM (TTM) | 14.07% | ||
| GM | 71.46% |
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
2. BTMD Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
- The number of shares outstanding for BTMD has been increased compared to 1 year ago.
- BTMD has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, BTMD has an improved debt to assets ratio.
2.2 Solvency
- BTMD has an Altman-Z score of 2.55. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
- BTMD has a Altman-Z score of 2.55. This is in the better half of the industry: BTMD outperforms 68.39% of its industry peers.
- BTMD has a debt to FCF ratio of 4.43. This is a neutral value as BTMD would need 4.43 years to pay back of all of its debts.
- BTMD's Debt to FCF ratio of 4.43 is amongst the best of the industry. BTMD outperforms 84.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.43 | ||
| Altman-Z | 2.55 |
ROIC/WACC6.05
WACC7.41%
2.3 Liquidity
- BTMD has a Current Ratio of 1.22. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.22, BTMD is not doing good in the industry: 77.20% of the companies in the same industry are doing better.
- BTMD has a Quick Ratio of 1.22. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of BTMD (0.79) is worse than 81.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.22 | ||
| Quick Ratio | 0.79 |
3. BTMD Growth Analysis
3.1 Past
- BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.27%, which is quite impressive.
- BTMD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -26.76% yearly.
- BTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.22%.
- The Revenue has been growing by 10.51% on average over the past years. This is quite good.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
3.2 Future
- BTMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.65% yearly.
- The Revenue is expected to grow by 8.86% on average over the next years. This is quite good.
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. BTMD Valuation Analysis
4.1 Price/Earnings Ratio
- BTMD is valuated cheaply with a Price/Earnings ratio of 1.77.
- 98.45% of the companies in the same industry are more expensive than BTMD, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 25.50. BTMD is valued rather cheaply when compared to this.
- BTMD is valuated cheaply with a Price/Forward Earnings ratio of 5.76.
- 93.26% of the companies in the same industry are more expensive than BTMD, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 22.67, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.77 | ||
| Fwd PE | 5.76 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 96.89% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.05 | ||
| EV/EBITDA | 4.07 |
4.3 Compensation for Growth
- BTMD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
5. BTMD Dividend Analysis
5.1 Amount
- BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BTMD Fundamentals: All Metrics, Ratios and Statistics
1.47
-0.13 (-8.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11 2026-03-11/amc
Earnings (Next)05-05 2026-05-05
Inst Owners63.61%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap58.14M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target4.94 (236.05%)
Short Float %5.15%
Short Ratio7.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)-13.64%
EPS NQ rev (3m)-13.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.6%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-3.12%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-2.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.77 | ||
| Fwd PE | 5.76 | ||
| P/S | 0.3 | ||
| P/FCF | 2.05 | ||
| P/OCF | 1.65 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.07 |
EPS(TTM)0.83
EY56.46%
EPS(NY)0.26
Fwd EY17.35%
FCF(TTM)0.72
FCFY48.73%
OCF(TTM)0.89
OCFY60.53%
SpS4.86
BVpS-1.48
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.13% | ||
| ROE | N/A | ||
| ROCE | 56.77% | ||
| ROIC | 44.85% | ||
| ROICexc | 72.95% | ||
| ROICexgc | 117.64% | ||
| OM | 18.5% | ||
| PM (TTM) | 14.07% | ||
| GM | 71.46% | ||
| FCFM | 14.74% |
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.43 | ||
| Debt/EBITDA | 2.57 | ||
| Cap/Depr | 187.03% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 4.51 | ||
| Cash Conversion | 89.73% | ||
| Profit Quality | 104.75% | ||
| Current Ratio | 1.22 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 2.55 |
F-Score7
WACC7.41%
ROIC/WACC6.05
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year51.43%
EBIT Next 3Y25.51%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%
BIOTE CORP -A / BTMD Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 6 / 10 to BTMD.
Can you provide the valuation status for BIOTE CORP -A?
ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.
How financially healthy is BIOTE CORP -A?
The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.
How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.